Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29396901 | 1.00 | LTB4R (1.00) | LTB4RLTB4R2 | |
| SCHEMBL9022847 | 0.92 | LTB4R (0.84) | LTB4RLTB4R2 | |
| SCHEMBL9023332 | 0.91 | LTB4R (0.83) | LTB4RLTB4R2 | |
| SCHEMBL9022467 | 0.89 | LTB4R (0.80) | LTB4RLTB4R2 | |
| SCHEMBL9023608 | 0.84 | LTB4R (1.00) | LTB4RLTB4R2 | |
| SCHEMBL9023836 | 0.84 | LTB4R (1.00) | LTB4RLTB4R2 | |
| SCHEMBL14021681 | 0.83 | LTB4R (0.88) | LTB4RLTB4R2 | |
| SCHEMBL14021678 | 0.83 | LTB4R (0.81) | LTB4RLTB4R2 | |
| SCHEMBL9023335 | 0.82 | LTB4R (1.00) | LTB4RLTB4R2 | |
| SCHEMBL1894403 | 0.82 | LTB4R (0.69) | LTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001034133-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | claimed |
| WO-2001034134-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | claimed |
| WO-2001034199-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | claimed |
| EP-0548250-B1 | SUBSTITUTED BICYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B4 ANTAGONIST ACTIVITY | RHONE POULENC RORER INT (US) | 1996-03-27 | — | — | EP | claimed |
| US-5468898-A | Substituted naphthylene compounds exhibiting selective leukotriene B4 antagonist activity | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-11-21 | — | — | US | claimed |
| EP-2471954-B1 | Genetic susceptibility variants associated with cardiovascular disease | DECODE GENETICS EHF (IS) | 2016-08-24 | — | — | EP | disclosed |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | MEDA AB (SE) | 2016-06-16 | — | — | US | disclosed |
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | MEDA AB (SE) | 2016-06-16 | — | — | US | disclosed |
| EP-2155907-B1 | GENETIC VARIANTS USEFUL FOR RISK ASSESSMENT OF CORONARY ARTERY DISEASE AND MYOCARDIAL INFARCTION | DECODE GENETICS EHF (IS) | 2015-05-27 | — | — | EP | disclosed |
| EP-2471954-A1 | Genetic susceptibility variants associated with cardiovascular disease | Decode Genetics EHF (IS) | 2012-07-04 | — | — | EP | disclosed |
| US-20110105959-A1 | Novel Methods for Bone Treatment by Modulating an Arachidonic Acid Metabolic or Signaling Pathway | ACCELALOX, INC. (US) | 2011-05-05 | — | — | US | disclosed |
| US-20090280153-A1 | electrical devices, anti-scarring agents, and therapeutic compositions | ANGIOTECH INTERNATIONAL AG (CH) | 2009-11-12 | — | — | US | disclosed |
| WO-2001034133-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
| WO-2001034134-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
| WO-2001034199-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
| EP-0548250-B1 | SUBSTITUTED BICYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B4 ANTAGONIST ACTIVITY | RHONE POULENC RORER INT (US) | 1996-03-27 | — | — | EP | disclosed |
| US-5468898-A | Substituted naphthylene compounds exhibiting selective leukotriene B4 antagonist activity | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-11-21 | — | — | US | disclosed |
| EP-0548250-A4 | SUBSTITUTED BICYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B 4? ANTAGONIST ACTIVITY | — | 1993-10-27 | — | — | EP | disclosed |
| EP-0548250-A1 | SUBSTITUTED BICYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B 4? ANTAGONIST ACTIVITY. | RHONE POULENC RORER INT (US) | 1993-06-30 | — | — | EP | disclosed |
| WO-1992004321-A1 | SUBSTITUTED BICYCLIC ARYL COMPOUNDS EXHIBITING SELECTIVE LEUKOTRIENE B4 ANTAGONIST ACTIVITY | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1992-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166508-A1 | Method and Composition for Treating Inflammatory Disorders | LIPA, HRH2, HRH1 | LTB4R 8/4885LTB4R2 7/4885 |
| US-20090280153-A1 | electrical devices, anti-scarring agents, and therapeutic compositions | GAP43, TNNC1, GJB2 | LTB4R 352/4885LTB4R2 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.